Swedish Orphan Biovitrum AB (SOBIV)

Stockholm
Currency in SEK
272.60
-9.00(-3.20%)
Closed·
SOBIV Scorecard
Full Analysis
Trading at a low P/E ratio relative to near-term earnings growth
SOBIV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
271.20280.40
52 wk Range
241.80354.40
Key Statistics
Edit
Prev. Close
281.6
Open
278.4
Day's Range
271.2-280.4
52 wk Range
241.8-354.4
Volume
412.36K
Average Vol. (3m)
356.13K
1-Year Change
-0.29%
Book Value / Share
113.64
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SOBIV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
353.09
Upside
+29.53%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Swedish Orphan Biovitrum AB News & Analysis

Show more

Swedish Orphan Biovitrum AB Company Profile

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Stockholm, Sweden.

Employees
1895
Market
Sweden

Compare SOBIV to Peers and Sector

Metrics to compare
SOBIV
Peers
Sector
Relationship
P/E Ratio
23.6x20.2x−0.5x
PEG Ratio
0.300.470.00
Price / Book
2.4x4.0x2.6x
Price / LTM Sales
3.6x4.6x3.0x
Upside (Analyst Target)
32.1%19.4%51.9%
Fair Value Upside
Unlock26.2%8.9%Unlock

Analyst Ratings

9 Buy
1 Hold
1 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 353.09
(+29.53% Upside)

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
2.55 / 2.40
Revenue / Forecast
6.47B / 6.35B
EPS Revisions
Last 90 days

SOBIV Income Statement

People Also Watch

66.800
VERB
-0.89%
480.20
PNN
-1.60%
137.80
DSG
+0.58%
501.00
INVP
+0.97%

FAQ

What Is the Swedish Orphan Biovitrum (SOBIV) Stock Price Today?

The Swedish Orphan Biovitrum stock price today is 272.60

What Stock Exchange Does Swedish Orphan Biovitrum Trade On?

Swedish Orphan Biovitrum is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Swedish Orphan Biovitrum?

The stock symbol for Swedish Orphan Biovitrum is "SOBIV."

What Is the Swedish Orphan Biovitrum Market Cap?

As of today, Swedish Orphan Biovitrum market cap is 93.63B.

What Is Swedish Orphan Biovitrum's Earnings Per Share (TTM)?

The Swedish Orphan Biovitrum EPS (TTM) is 11.56.

When Is the Next Swedish Orphan Biovitrum Earnings Date?

Swedish Orphan Biovitrum will release its next earnings report on Jul 16, 2025.

From a Technical Analysis Perspective, Is SOBIV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Swedish Orphan Biovitrum Stock Split?

Swedish Orphan Biovitrum has split 2 times.

How Many Employees Does Swedish Orphan Biovitrum Have?

Swedish Orphan Biovitrum has 1895 employees.

What is the current trading status of Swedish Orphan Biovitrum (SOBIV)?

As of Jun 20, 2025, Swedish Orphan Biovitrum (SOBIV) is trading at a price of 272.60, with a previous close of 281.60. The stock has fluctuated within a day range of 271.20 to 280.40, while its 52-week range spans from 241.80 to 354.40.

What Is Swedish Orphan Biovitrum (SOBIV) Price Target According to Analysts?

The average 12-month price target for Swedish Orphan Biovitrum is SEK353.09091, with a high estimate of SEK383 and a low estimate of SEK285. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +29.53% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.